(MECK) Inside Bitcoins Conference & KINTEX Announce Cryptocurrency Trade Show in South Korea

NEW YORK, Oct. 15, 2014  — MecklerMedia (OTCQX: MECK) announced that the Inside Bitcoins Conference and Expo taking place in Seoul on December 12-13 will be South Korea’s first major cryptocurrency event.

Inside Bitcoins Seoul will be co-produced by MecklerMedia and the Korea International Exhibition Center (KINTEX).

The event will feature a lineup of both local and international experts, including Jacob Hansen, CEO & Co-Founder, CrowdCurity; Prof. Hoh Peter In, Ph.D. Professor, Department of Computer Science, College of Informatics, Korea University; Zennon Kapron, Managing Director, Kapronasia; Mr. Casey Ilsun Kim, CEO, InfraBasic and Adjunct Professor, Hanyang University Business School; Tony Lyu, CEO, Korbit; and more.

Early bird prices will expire on October 31, so attendees are encouraged to register before then for the best rate. For complete information on Inside Bitcoins Conference and Expo, visit insidebitcoins.com.

If your company is interested in sponsoring or exhibiting, contact us at eventsales@mecklermedia.com.

About MecklerMedia
MecklerMedia (OTCQX: MECK) is the producer of conferences including Inside 3D Printing, Inside Bitcoins, and AllFacebook Marketing Conference. MecklerMedia produces over 25 conferences annually. The MecklerMedia news sites and newsletters, including Inside Bitcoins News, 3D Printing Industry, and Allfacebook.de provide up-to-date coverage on emerging industries to help drive business forward.

(NVIV) Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.

Dr. Nicholas Theodore, Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program, is a Principal Investigator in this study and implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient. “I am excited about my participation in this important clinical trial,” Dr. Theodore said. “The surgery and Neuro-Spinal Scaffold implantation went smoothly and the patient is doing well at this time. I look forward to continuing to help evaluate this approach in patients with these devastating injuries.”

Mark Perrin, InVivo’s CEO, said: “This is a major milestone not only for the company, but also for the field of traumatic SCI. InVivo is striving to provide benefit to the SCI patient population with such a huge unmet medical need, and this clinical trial is the first step. We look forward to communicating our progress and moving forward. InVivo will be making announcements after each site has joined the study, after each subject is enrolled, and once enrollment is re-opened for subsequent patients. We consider patient privacy of the utmost importance and will thus communicate any interim information according to industry standards. With the exception of dramatically positive or negative results, we will look to communicate progress at appropriate medical or scientific forums.”

As previously stated and per FDA requirements, the company will follow the first enrolled subject for three months before re-opening enrollment.

For more information, please visit our ClinicalTrials.gov registration site:
http://clinicaltrials.gov/ct2/show/study/NCT02138110

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the Company’s expectations with respect to the safety, feasibility, and clinical effectiveness of its scaffold device, the enrollment of subsequent patients in the scaffold pilot study following the reopening of enrollment, and the potential market for the treatment of spinal cord injuries. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

(OEDV) Announces New Well Rates of 1306 BOE

Osage Exploration and Development, Inc. (OTCBB:OEDV), an independent exploration and production company focused on the Horizontal Mississippian and Woodford plays in Oklahoma, announced today preliminary production results from the McNally 1-29MH and the McNally 1-20WH, located in Logan County, Oklahoma.

The McNally 1-29MH, a horizontal Mississippian well in Section 29-17N-2W, has reached a one-day production rate of 695 BOE. The product mix is 84% crude oil and 16% natural gas. Osage has approximately a 58% Working Interest in the well.

The McNally 1-20WH, a horizontal Woodford well in Section 20-17N-2W, has reached a one-day production rate of 611 BOE. The product mix is also 84% crude oil and 16% natural gas. Osage has approximately a 76% Working Interest in the well.

Management Comments

“Since Osage took operational control in Logan County we have reiterated that the second half of 2014 would be a time of great change for our shareholders. We ended the first half of this year producing about 425 barrels of oil equivalent net to Osage from 43 non-operated wells. With only four Osage-operated wells added to that total, we have more than tripled our daily production to 1,392 barrels of oil equivalent, far in excess of the target year-end exit rate that we promised publicly just 45 days ago,” stated Kim Bradford, Chairman and CEO.

“Our Mississippian well, while still early in its production life, is well ahead of the type curve and promises to be an exceptional well with early payback. Our Woodford well is without a doubt the best Woodford well drilled in southern Logan County, and better by far than any Woodford well drilled by any offset operator outside of Devon Energy. The impact of this is enormous to the Osage shareholder because it proves our assertion that we can drill multiple Mississippian wells and multiple Woodford wells in every section that we operate,” stated Jack Zedlitz, VP Corporate Development.

“The quality of our rock has never been seriously questioned, but it took the right operational team with the right philosophy to bring everything to fruition,” stated Greg Franklin, Osage’s Vice President of Exploration and Senior Geologist.

“Looking beyond these exceptional results, we already have two more Mississippian wells drilled which we will frac later this month, and our next two drilling pads under construction to move our rig to sequentially. We have built a team of exceptional individuals to execute this plan and our results speak for themselves. Even with the high level of production that we are seeing, our primary focus is on cutting drilling and completion costs, which is crucial in this volatile commodity price environment. While these are still the early days of our development program, we have put exclamation points on our geology, our team, and our ability to deliver results, all to the benefit of our shareholders,” concluded Kim Bradford.

About Osage Exploration and Development, Inc.

Based in San Diego, California, with production offices in Oklahoma City, Oklahoma, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the U.S. http://www.osageexploration.com

Safe Harbor Statement

The information in this release includes certain forward-looking statements as defined by the Securities and Exchange Commission that are based on assumptions that in the future may prove not to have been accurate. Those statements and Osage Exploration and Development, Inc. are subject to a number of risks, including production variances from expectations, volatility of product prices, inability to raise sufficient capital to fund its operations, environmental risks, competition, government regulation, and the ability of the Company to execute its business strategy, among others.

(LOTE) Expands Distribution with Harvey Nichols in Dubai for Autumn/Winter ’14

NEW YORK, Oct. 15, 2014  — Lot78, Inc. is pleased to announce that the Company has secured retail distribution with Harvey Nichols in Dubai.

Harvey Nichols: Harvey Nichols has stores in London, Leeds, Edinburgh, Birmingham, Manchester and Bristol. It also has a store in Al-Faysaliyah Tower in Riyadh, Saudi Arabia, a store at Dundrum Town Centre, Dublin in Ireland and one in Central, Hong Kong. It opened a store in Istanbul’s Kanyon Shopping Mall on 13 October 2006. In February 2006, it opened a store in Dubai, designed by architecture firm Callison in the Mall of the Emirates. The Dubai store is operated by Al Tayer Insignia, (Al Tayer group LLC) the luxury retail arm of Al Tayer Group.

“We are excited to increase our mainstream profile and expand our brand reach in Dubai with our women’s collection which will add to our existing men’s business,” says Ollie Amhurst, President and CEO of Lot78, Inc.

About Lot78, Inc.

Lot78, Inc. is a trend-setting leader in the design, marketing, distribution and sale of urban apparel – retailing under the brand name “Lot78” in six continents, including: North America, Europe, Asia, Australia, Africa and South America. Lot78 has been featured in US Weekly, Elle Magazine, Financial Times, Harrods Magazine, The London Evening Standard, and Grazia Magazine as an emerging global brand. Lot78, Inc. is quoted on the OTC Bulletin Board in the United States of America under the symbol LOTE.OB. For more information, please visit www.lot78.com.

Forward-Looking Statements

This news release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Lot78’s products to gain market acceptance, and the difficulties faced by an early stage retail fashion company in the competitive retail fashion industry. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s recent current reports on Form 8-K, our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic and current reports filed from time to time with the Securities and Exchange Commission.

(CTRV) Closes $9.0 Million Financing to Advance Lead Shingles Candidate

Proceeds to Fund Phase 2b Study of FV-100 Fast-Acting Oral Antiviral

EDISON, N.J., Oct. 15, 2014  — ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million.  The Preferred Stock is convertible at any time into shares of common stock at a conversion price of $0.48 per share.  The investor has agreed to lock-up the shares of Preferred Stock and the underlying common stock until April 14, 2016.

ContraVir intends to use the net proceeds of the transaction to fund the initiation of a Phase 2b clinical study for the Company’s lead clinical asset, FV-100, a fast-acting, once-daily oral antiviral agent being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. FV-100 also has the potential to further reduce the incidence, severity, and duration of shingles-associated pain and prevent post-herpetic neuralgia (PHN).

“This $9.0 million financing is the first step in a corporate and clinical strategy to accelerate the growth of ContraVir and seize upon the significant potential of FV-100,” stated James Sapirstein, chief executive officer of ContraVir Pharmaceuticals. “Not only are we now capitalized to initiate the Phase 2b clinical trial of FV-100 in shingles, but we are also well positioned to target additional opportunities to add to our pipeline and build ContraVir as a multifaceted antiviral company.”

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. For additional information, please refer to ContraVir’s current report on Form 8-K to be filed with the Securities and Exchange Commission with respect to the private placement.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. ContraVir’s lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV). Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, famcyclovir, and valacyclovir, the FDA approved drug for treating shingles. Moreover, FV-100 has been shown to have a more rapid onset of antiviral activity in preclinical models, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels and with a better dosing regimen. Phase 1 trials of FV-100 in volunteers were successfully completed, as well as a Phase 2a clinical trial in shingles patients. ContraVir plans to conduct a Phase 2b trial in patients with shingles to further explore FV-100’s potential to treat the long-lasting nerve pain typically associated with shingles. ContraVir was formed in May 2013 by Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) and spun off as an independent public company in January 2014. For more information, please visit www.contravir.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on ContraVir’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir’s Form 10-K for the fiscal year ended June 30, 2014, and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686

(CALI) Global Lock Notice Suspended by Depository Trust Company

(WDRP) Signs Crop Share Agreement with California Dispensary

SANTA MONICA, CA, United States, via ETELIGIS INC., 10/14/2014 – – WanderPort Corp. (OTC Pink: WDRP) (PINKSHEETS: WDRP), today announced that it has signed a Crop Share Agreement with a Southern California dispensary.

The crop share agreement as provided under California Proposition 215 and Senate Bill 420, allows for the cooperative cultivation, possession, transportation and use of marijuana for medical purposes within the state of California.

“Crop sharing is a great way for Wanderport to participate in the fast growing medical marijuana industry, said Eric Brown, Chief Executive Officer. This is one of many investments we will make to build a solid and diversified portfolio of bona fide cannabis related assets added Brown.

About Wanderport Corp.

Wanderport Corporation specializes in licensing, distribution and obtaining proprietary rights to various unique technology while continuing to be an acquisition minded company targeting various licenses, technologies and/or companies in key emerging growth industries.

Forward-Looking Statements:

Statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company’s stock price, increased competition, customer acceptance of new products and services to be offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating efforts.Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management’s plans and objectives for future operations.In some cases you can identify forward-looking statements by the use of terminology such as “may”, “should”, “anticipates”, “believes”, “expects”, “intends”, “forecasts”, “plans”, “future”, “strategy”, or words of similar meaning.While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of Wanderport Corporation, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this press release.These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that Wanderport Corporation cannot execute its business plan for lack of capital or other resources, distribution, licensing/acquisition opportunities or internal partnering issues or restructuring/resignation which may modify existing licensing agreement, arrangements and/or contractual obligations, as well as the risks described in the periodic disclosure documents filed on OTCMarkets.com by Wanderport Corporation. Any of these risks could cause Wanderport Corporation or its industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this press release. Except as required by applicable law, including the securities laws of the United States, Wanderport Corporation does not intend to update any of the forward-looking statements to conform these statements to actual results.

CONTACT:

Wanderport Corporation

www.wanderportcorp.com

Investor Relations:

info@wanderportcorp.com

(310) 526-8720

(VSYM) Announces Letter of Intent to Merge With Potomac River Group

(STLK) Issues Investor Update

COLORADO SPRINGS, Colo., Oct. 14, 2014  — STL Marketing Group, Inc. (OTC: STLK) is issuing a brief investor update on its progress since its Shareholder Conference Call this past August. The Company has been working on various goals since its last update and has made progress on establishing new dealers for its new PhoneSuite Solutions business, as well as, its new Letter of Interest from the Export-Import Bank (Ex-Im Bank). This update is to report on key items discussed at that meeting.

“The last 60 days has seen steady work behind the scenes with regard to the PhoneSuite Solutions development. Some of this development has been to our internal office infrastructure, for example we have implemented SIP trunking and our Voiceware by PhoneSuite^® VoIP PBX has been installed with a fully functional IVR. Our web page redeployment is close at hand and will more accurately reflect the corporate structure with separate sites for PhoneSuite Solutions and Energía Renovable Versant. Along with our existing IR efforts, we have also begun to implement a software application to help us better manage our Social Media and we hope to have ongoing updates through those channels on a consistent basis as a result. These developments are designed to help us handle the expected sales for the PhoneSuite brand of products, as well as help to keep our shareholders updated.

More importantly, from a revenue perspective, we have begun to establish the necessary dealers in various parts of the world, the first being Exodus for the UAE and Indian markets. We are working with dealers in other areas (e.g. Australia, Malta, Saipan, etc.) and expect to have more announcements on new dealers as we get dealer contracts in place. The dealer process does require a dealer agreement; this makes the process slow at the onset, but is more meaningful than a non-contracted “appointment” to distribute the line. Additionally, our outreach effort for new SMB business here in the USA, through Response Logic, began a little over a week ago, and is yielding good leads for the product.  We are positive on the progress made thus far, and hope to report more positive progress in the months to follow.

As to energy, we are working on getting our status as per our last shareholder call. We have confirmed the delay on new projects as previously reported from various sources. Unfortunately, this area continues to be a slow process. We do hope to have a project status update before year-end. We have been working with the Export-Import Bank for a new Letter of Interest, as our last letter has expired. Ex-Im has undergone some reorganization and changed their internal process which have caused delays, but we feel confident we should get that important letter of support soon,” said Jose P. Quiros, CEO of STL Marketing Group, Inc.

About STL Marketing Group, Inc./ Versant Corporation
STL Marketing Group, Inc. is a Colorado based company that sells, distributes and markets the PhoneSuite brand of VoIP telecommunications equipment (through its wholly owned subsidiary PhoneSuite Solutions, Inc.,), as well as, working on the development of renewable energy opportunities (through its wholly owned subsidiary Energia Renovable Versant SRL).  For more information on STLK, please visit our web site at www.STLmarketingGroup.com or www.v3rsant.com .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plan, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

(NNLX) Being Configured For Rapid Ebola Virus Detection

NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”

The NanoLogix N-Assay (V) ELISA is one of six technologies that may be used for virus detection and identification, the N-Assay (V) has unique qualities that contribute to both its rapid detection capability and long term durability that should be attractive to personnel in both developed and remote locations interested in a screening test that may provide results for Ebola or other viral threats in 30 minutes to a few hours.

Supporting information on the N-Assay (B), used for bacterial detection and identification and evidence of the capabilities of one version of the technology can be found by following this link:

http://nanologix.com/resources/index.html

Sebastian Faro, MD, PhD, is considered one of the top experts in the world on Infectious diseases of women’s reproductive systems. Dr. Faro made the following comments: “N-Assay ELISA technology has been applied to the rapid identification of specific bacteria, e.g. Streptococcus agalactiae (GBS), Neisseria gonorrhoeae, & Enterococcus faecalis. This technology has been used to rapidly identify strains that are resistant to specific antibiotics. This technology significantly reduces the time from specimen submission to identifying these bacteria and resistance to specific antibiotics. This N-Assay ELISA technology can be applied to identifying viruses and is inexpensive. This technology does not require expensive equipment which makes this technology ideal for a variety of laboratory environments.”

His presentation on the N-Assay is in the following YouTube links:

https://www.youtube.com/watch?v=TCG_ihwwrBQ

https://www.youtube.com/watch?v=kshzguaO7uk

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

For more information visit: http://www.nanologix.com

This press release contains statements, which may constitute “forward- looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

(CNET) Launches Zero Down Payment Loans in Cooperation With Haodai and Yooli

BEIJING, Oct. 14, 2014  — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (“ChinaNet” or the “Company”), a leading B2B (business to business) Internet technology company providing online-to-offline (O2O) sales channel expansion services for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking services for entrepreneurs in the People’s Republic of China, today announced the launch of Zero Down Payment Loans. The product, targeted toward entrepreneurs, is being offered with Chinese financial services companies Haodai, which offers a credit product search engine, and Yooli China’s leading crowdfunding services Web site.

ChinaNet is taking a leading role in the Zero Down Payment Loans offering. The product integrates banks, P2P, and security companies with reputable enterprise franchising resources. The service will significantly lower the hurdles that many entrepreneurs face and help them to realize their business objectives.

Neither Haodai nor Yooli provide loans, but focus on helping individuals and small-to-medium sized businesses screen loan opportunities in the financial markets. The new Zero Down Payment Loans product will facilitate communications between potential borrowers and lenders. ChinaNet customers will benefit significantly as many are in need of capital for expansion hundreds of thousands of entrepreneurs who need capital will benefit from ChinaNet’s cooperation with other financial service providers, and will be able to achieve their business goals more quickly.

ChinaNet COO George Chu says, “In 2014, the number of mobile Internet users in China exceeded 600 million, while there are approximately 200,000 physical outlets of traditional banks. These 600 million smart phones will become the new point of contact in the financial services sector. Everyone is jumping on the P2P bandwagon: private equity firms, venture capitalists, companies like Lenovo, Xiaomi and other Internet giants as well as traditional companies with physical capital and even Hong Kong developer SHK. With the advent of the big data era, personal credit information systems will gradually improve, and with these information sharing systems freely accessible, P2P will continue to grow. Such cooperation will bring an additional revenue stream to the company as P2P markets grow and expand. The beauty of this cooperation is the ability to leverage ChinaNet’s existing resources, which produce daily sales leads that yield potential borrowers.”

About Yooli

Founded in 2012 by a group of finance and technology professionals, the Company’s goal is to become the leading crowd-funding Web site in China. Yooli is a P2P (person-to-person) online crowd-funding platform that provides financial products for Chinese microfinance investors. Individual borrowers or small business owners can submit loan applications on Yooli.com and, once approved, the applications are posted for lenders review. Borrowers pay interest on monthly basis upon receipt of the loan. (www.yooli.com)

About Haodai

Based in Beijing, Haodai offers a credit product search engine that makes it possible to identify the best loan channels and match banks and financial institutions with borrowers. Users submit a brief application and are contacted by consultants who review their needs and create customized lending solutions. The Company has facilitated approximately $16.33 million in loans, and works with more than 3000 lenders across China. (www.haodai.com)

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading digital B2B (business to business) Internet technology company focusing on providing RMB sales channel expansion service for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese SMEs via its portal websites, 28.com, Liansuo.com and Chuangye.com, TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Direct: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us

(AEMD) Announces First Treatment of an Ebola Patient

SAN DIEGO, Oct. 14, 2014  — Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus.  The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany.  The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.  The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.

“We thank the physicians in Frankfurt for allowing us the opportunity to treat this advanced-stage patient,” stated Aethlon founder and CEO, Jim Joyce.  “Details related to the patient’s response to therapy will be disclosed once hospital officials deem it appropriate to report an update on the condition of this individual.”

In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating ebola to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response.  The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.

Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration’s (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company.  The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India.  In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

About Aethlon Medical, Inc.

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders.  The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.  Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.  For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

(MMRF) Launches Television Advertising for Interoperable Personal Health Record

(MTVX) To Debut Seven New Products at 2014 AIMExpo

KANSAS CITY, Mo., Oct. 13, 2014  — APT MotoVox Group, Inc. (OTC BB: MTVX) is preparing to make a scene in four days at the 2014 American International Motorcycle Expo (AIMExpo) in Orlando, Florida, America’s No. 1 motorcycle show.  For the first time ever, the company will be presenting seven all-new recreational and light transportation models from its new product lines.

Troy Covey, president of APT, said that company leadership believes that their presentation will be remembered for years to come.  “The motorsport industry is due for a change,” he said.  “The model is old and in many ways broken.  The industry needs something fresh in presentation and product.  We are going to give it to them.”

Covey added, “Nearly 400 international and domestic dealers have already made contact with us to discuss distribution.  That’s an impressive number.  This is a clear indication of the extraordinary interest and continues to validate our projected growth plan for 2015.”

APT will have the attention of over 3,400 dealers and tens of thousands of consumers at the AIMExpo, which will run from Oct. 16-17 for dealers and Oct. 18-19, 2014 for consumers.  At Booth 771, APT will have its complete family line of APT MotoVox, Pro, Motopeds, and SmartCarb technologies.  In addition, APT will transform Booth 2385 into the Motoped Zombie Survival Zone, where dealers and consumers alike can register to win a free Motoped and play interactive zombie games.

APT is also hosting a happy hour for the 3,400 dealers in attendance as well as co-sponsors of the show on Thursday, Oct. 16, 2014 from 6-8 p.m.

About APT MotoVox Group, Inc.:

APT MotoVox Group, Inc. (OTC BB: MTVX) is a Delaware registered corporation headquartered in Kansas City and is the holding company for the MotoVox® and MOTOPED® motorsport product lines, SmartCarb® patented fuel system, and the Sonic Flow small engine technology lines (http://www.motovox.com/, http://www.powerapt.com/ and http://www.motoped.com).

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as “anticipate,” “believe,” “expect,” “future,” “intend,” “plan,” and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company’s public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company’s past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Contact

William Maher, SVP
APT MotoVox Group, Inc.
InvRel@motovox.com

Paul Knopick
E & E Communications
940.262.3584
pknopick@eandecommunications.com

(REVO) Board Approves $7.0 Million Share Buyback Plan

$7.0 Million Repurchase Price Represents Nearly 10 Times the Current Share Price

CHARLOTTE, N.C., Oct. 13, 2014  — Revolutionary Concepts Inc., (OTCPINK:REVO), a publicly traded company that develops mobile video software and remote security communication systems, announced its Board of Directors has approved the repurchase of up to 140 million shares of its outstanding shares of common stock for a repurchase price of up to $7.0 million to boost shareholder value.

The Board of Directors has approved the repurchase of up to 20% or 140 million of its total outstanding shares. The main purpose of the repurchase plan is the return of capital to the shareholders, reduce the amount of outstanding shares and to improve the companies the capital structure. The repurchase of up to 140 million shares of stock at up to $7.0 million reflects a repurchase price of up to $0.05 per share, or nearly 10 times the current share price.

REVO’s Senior Vice President, Solomon Ali states, “We feel excited about the repurchase of up to $7 million of our shares, as this reflects a repurchase price of up to $0.05 per share, which is almost 10 times the current share price of our stock. We are very positive about the future of REVO, as we are forecasting that $60 to $80 million in estimated annual revenues from licensing fees and royalties could be generated from our global licensing agreement. In September, our global licensee filed complaints in the United States District Court against four companies for allegations of patent infringement against REVO’s intellectual property. All of this is welcome news that could work to the benefit of the Company and its shareholders.”

The Company may buy shares on the open market or in privately negotiated purchases. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions, stock price, corporate and regulatory requirements, economic conditions and other factors. Repurchases will be made in compliance with all SEC rules and other legal requirements and may be made in part under a Rule 10b5-1 plan, which permits stock repurchases when the Company might otherwise be precluded from doing so. Any open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Securities and Exchange Commission and other applicable legal requirements.

About Revolutionary Concepts Inc.

REVO’s primary business is the design and development of the “EyeTalk” Communicator technology,  a mobile video, remote smart camera security technology. The system is designed to provide nationwide protection and monitoring of homes and businesses against multiple threats including robbery, fire, theft, burglary and other intrusions through  mobile phones, wireless video and remote smart camera security technology. REVO holds patented and patent pending applications that utilize the technology in medical/healthcare, sporting events, child monitoring and several other key areas. For more information visit www.revolutionaryconceptsinc.com.

For inquiries contact: Media Relations: Solomon Ali at 980-225-5376

Safe Harbor Statement – There are matters discussed in this media information that are forward looking statements within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. Such statements are only forecasts and actual events or results may differ materially from those discussed. For a discussion of important factors which could cause actual results to differ from the forward looking statements, refer to Revolutionary Concepts Inc.’s most recent annual report and accounts and other SEC filings. The company undertakes no obligation to update publicly, or revise, forward looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.

(NSPH) FDA Clears Additional Viral Targets on Verigene Enteric Pathogens Test

NORTHBROOK, Ill., Oct. 13, 2014  — Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Verigene® Enteric Pathogens Nucleic Acid Test (EP), which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer.

Verigene EP is a rapid, easy-to-use and cost-effective alternative to traditional stool diagnostics that the Company believes has the potential to deliver clinical, economic and workflow benefits to hospitals and laboratories.

“Rapid diagnostic tests that accurately detect the organisms that cause diarrheal illness have the ability to improve physician decisions regarding patient management,” said Paul A. Granato, PhD, D(ABMM), Director of Microbiology and Scientific Director of Clinical Microbiology at Laboratory Alliance, whose laboratory participated in the Verigene EP clinical trial. “In addition to potentially reducing use of unnecessary or inappropriate antibiotics, these tests can help optimize laboratory staff and budgetary resources by reducing the time and costs associated with working up both negative and positive stool specimens.”

Verigene EP is Nanosphere’s second FDA-cleared test in the area of gastroenteritis, joining the currently marketed Verigene Clostridium difficile Nucleic Acid Test (CDF), which identifies toxigenic C. difficile and differentiates the 027 hypervirulent strain for epidemiological purposes.

“The feedback we’ve received from the medical community regarding our approach to designing Verigene EP to provide clinically actionable results for common community-acquired gastrointestinal infections has been very encouraging,” said Michael McGarrity, Nanosphere’s president and chief executive officer. “We anticipate that the addition of Verigene EP to our infectious disease test menu will provide additional value to our customers and patients.”

Nanosphere’s menu includes five multiplex molecular diagnostic tests performed using the automated, sample-to-result Verigene System that target infections of the bloodstream, respiratory tract and gastrointestinal tract. They include the Verigene Gram-Positive Blood Culture Test (BC-GP), the Verigene Gram-Negative Blood Culture Test (BC-GN), the Verigene Respiratory Virus Plus Test (RV+), Verigene CDF (each of which is FDA-cleared and CE-marked), and now Verigene EP. Nanosphere anticipates CE marking of Verigene EP in early 2015.

About the Verigene® System

The Verigene System uses Nanosphere’s core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene tests target infections of the bloodstream, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy and reduced spread of antibiotic resistance.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

Except for historical information, the matters discussed in this press release are “forward-looking statements” and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere’s ability to develop commercially viable products; (ii) Nanosphere’s ability to achieve profitability; (iii) Nanosphere’s ability to produce and market its products; (iv) Nanosphere’s ability to obtain regulatory approval of its products; (v) Nanosphere’s ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere’s ability to obtain additional financing to support its operations. Additional risks are discussed in the Company’s current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Investors:
         Roger Moody, Chief Financial Officer
         847-400-9021
         rmoody@nanosphere.us

         Michael Rice, LifeSci Advisors
         646-597-6979
         mrice@lifesciadvisors.com

         Media:
         Zachary Crowther, Director of Marketing
         847-400-9047
         zcrowther@nanosphere.us

(YEWB) Signs Exclusive Distribution Agreement with Carpal Aid

HARBIN, China, Oct. 13, 2014  — Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China, today announced a multi-year exclusive distribution agreement with Carpal Aid to distribute its non-invasive medical device “Carpal Aid” for carpal tunnel syndrome throughout China.

Carpal Tunnel Syndrome (CTS) is a common nerve disorder that affects approximately 3 to 6% of adults in the general population, according to American Family Physician, a medical journal. CTS is also a frequent pregnancy complication, with prevalence reported as high as 62%. The most typical symptoms are numbness and tingling in the thumb, index finger, middle finger, and radial half of the ring finger, burning dysesthetic wrist pain, as well as the loss of grip strength and dexterity. As symptoms worsen, decreased grip strength makes it difficult to form a fist, grasp small objects, or perform other manual tasks such as driving and dressing. CTS morbidity continues to increase as a result of higher computer use, driving, and other repetitive hand motion.

Developed to provide functional support and help for hand numbness, Carpal Aid is a single use disposable adhesive strip that creates a bridging action that lifts the skin above the median nerve to relieve pressure. Designed to be light-weight and invisible, the product promotes restful sleep and works on both hands.

“We believe Carpal Aid provides an important effective non-invasive option for those who suffer from this common nerve disorder, fulfilling a unique need as there are no effective non-surgical treatments for carpal tunnel in the market today,” said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. “We see a lot of potential for introducing innovative therapies, such as Carpal Aid, through our established distribution network, and look forward to introducing this exceptional product to patients and physicians in China.”

The company is currently working with the SFDA (China Food and Drug Administration) to obtain clearance for Carpal Aid.

ABOUT YEW BIO-PHARM GROUP, INC.

Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit http://www.yewbiopharm.com/.

(KITM) and Future Ads LLC Agree to Merge

-Future Ads Projected EBITDA of $30 million for FYE 2014 -Industry Leader Jared Pobre To Become Chairman of Combined Company -Combined Company to Enjoy Significant Revenue Opportunities and Cost Synergies

JERSEY CITY, N.J. and IRVINE, Calif., Oct. 13, 2014  — Kitara Media Corp. (OTC BB: KITM), a leading digital media and technology company providing video solutions to advertisers, digital marketers and publishers (“Kitara”), and Future Ads LLC, an Irvine, California based company in the advertising tech industry with unaudited projected revenues of approximately $90 million and unaudited projected EBITDA of approximately $30 million for the year ending December 31, 2014 (“Future Ads”), today jointly announced that they have entered into definitive agreements to merge their respective companies.

“For many years Future Ads and Kitara Media have delivered on exceptional performance and results for online advertisers and we are excited with the combination of the two companies and teams to further accelerate our products and solutions across mobile, display, video and data. Our assets and teams are complementary and the combination will strengthen our ability to drive outstanding advertiser performance as well as financial results,” said Jared Pobre, Future Ads founder and Chief Executive Officer.

“The online advertising market is craving strong integrated solutions that can provide successful performance across many channels. The combination of Future Ads and Kitara Media will form a powerful online advertising platform to provide superior display and video advertising performance solutions to both advertisers and publishers. We are very excited to bring the talents and passion of the teams together to grow the mutual businesses to the benefit of our customers,” said Bob Regular, Chief Executive Officer of Kitara.

After the transaction, the former members of Future Ads will own 53% of the fully diluted stock of the combined company. In addition, the members of Future Ads will receive cash at closing, deferred consideration that may be in cash or stock and have performance-based EBITDA “earn out” targets that would enable them to receive additional cash or stock consideration over the fiscal years ending 2015 to 2018, as more fully set forth in the definitive agreements. The Future Ads members will execute lock-up agreements alongside existing Kitara board member stockholders and other stockholders. Future Ads currently has no existing bank debt or long-term liabilities on its balance sheet.

Kitara has received a fully committed debt facility from a nationally recognized lender that is subject only to the execution of definitive loan documents and satisfaction of closing conditions.

Upon consummation of the transactions, Jared Pobre will become Chairman of the Board of the combined company and Robert Regular will become Chief Executive Officer of the combined company. The newly combined company intends to apply for a listing on the NASDAQ stock market once it meets all listing criteria. It also intends to change its name in connection with the transaction to reflect the combined companies business’ going forward.

The parties will seek to consummate the transactions by December 31, 2014. The transaction is subject to the satisfaction of customary closing conditions. There can be no assurance that a closing will occur.

Complete details and terms of the transaction, including the loan terms, will be contained in a Current Report on Form 8-K to be filed by Kitara on Tuesday due to the Columbus Day federal holiday closing of the Securities and Exchange Commission today.

Gibson, Dunn & Crutcher, LLP represented Future Ads in the transaction. Graubard Miller represented Kitara in the transaction.

About Kitara Media

Kitara Media is a leading digital media and technology company providing video solutions to advertisers, digital marketers and publishers. With nearly 500 million monthly video ad views, Kitara Media delivers strong engagement for advertisers, high revenues for publishers, as well as improved user experience with PROPEL+, an internally developed proprietary video ad technology platform. Kitara Media owns and operates several online media sites including Healthguru.com and Adotas.com. The company is headquartered in Jersey City, NJ. For more information visit http://www.kitaramedia.com.

About Future Ads

Future Ads is a digital media platform for results-focused online advertising and publisher monetization. Future Ads’ innovative, diversified solutions works synergistically to help advertisers and publishers achieve outstanding performance results. Founded in 2001, Future Ads is headquartered in Irvine, CA. For more information, visit http://www.futureads.com.

Forward Looking Statements 

This press release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of Kitara’s and Future Ads’ management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

Forward-looking statements are inherently uncertain and subject to a variety of events, factors and conditions, many of which are beyond the control of Kitara and Future Ads and not all of which are known to Kitara or Future Ads, including, without limitation those risk factors described from time to time in Kitara’s reports filed with the SEC.  Among the factors that could cause actual results to differ materially are: loss of key advertising customers; inability to acquire new advertising customers; inability to expand video content library; inability to achieve projected results; inability to protect intellectual property; inability to execute acquisition strategy; inability to effectively manage growth; failure to effectively integrate the operations of acquired businesses; competition; loss of key personnel; increases in costs of operations; continued compliance with government regulations; general economic conditions; and the possibility that the transaction does not close due to the failure to achieve the necessary closing conditions. Most of these factors are outside the control of Kitara and Future Ads and are difficult to predict. The information set forth herein should be read in light of such risks. Further, investors should keep in mind that the financial results included herein are unaudited, contain certain non-GAAP measures and may not conform to SEC Regulation S-X.  As a result, such information may be presented differently in Kitara’s periodic filings with the Securities Exchange Commission and may fluctuate materially depending on many factors. Accordingly, the financial results in any particular period may not be indicative of future results. Neither Kitara nor Future Ads assumes any obligation to update the information contained in this press release except as required by law.

(PNTV) Announces WeedTv Web Stream of the Historic First Annual Las Vegas Hempfest

LAS VEGAS, NV, United States, via ETELIGIS INC., 10/10/2014 – – Players Network (OTC-QB Bulletin Board: PNTV), a Digital Television, Technology and New Media company that develops, owns, and operates Branded Lifestyle Channel Destinations announces a special re-broadcast of the live webcast from the first annual Las Vegas Hempfest. The broadcast will be free and available on www.weedtv.com beginning today at 12:00 Noon PST and at 3pm EST and will continue through Sunday, October 12, 2014. The broadcast features exclusive behind the scene interviews from the Hempfest VIP Lounge, with Hempfest performance artists and special guest celebrities providing fans with unprecedented access, plus concert coverage.

Artists and featured guests include; Wonder Hussy, DJChef Fred, 420 Nurses, Marlon Asher, Nevada Senator Tick Segerblom, Rappin4Tay, Dan Rush a Director with United Food and Commercial Workers Union, Sen Dog of Cypress Hill, Pony Boy-Los Marijuanos, Roscoe and Y.A. Anterrazh, Baby Bash, Burner plus much, much more.

For a full Las Vegas Hempfest line up and schedule go to http://lasvegashempfest.com

Mark Bradley CEO of Players Network states, The first annual Las Vegas Hempfest was an amazing and historic event. We are proud partners with Las Vegas Hempfest and wish to congratulate Las Vegas Hempfest and its organizers on a great event. This was also an extremely successful event for WeedTv building stronger relationships with artists, connecting to their social media groups and rewarding our sponsors. I would also like to take this opportunity to also thank our sponsors and the entire WeedTv team. We plan many more live streaming events in the future as this is a great vehicle to build revenue and significantly increase audience.

About WeedTV:

WeedTv is the go to source for informational, entertainment, products and services for people who relate to the marijuana lifestyle and social community. Weed TV provides a wide variety of editorial content, videos and entertainment including lead stories, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, a Weed101 section, medical uses, lifestyle features, entertainment specials and merchandise shopping cart offering products and services.

About Players Network:

Players Network is a Television and Digital New Media Company that uses its proprietary Enterprise Web Platform to develop numerous Branded Digital Lifestyle Networks for itself and its partners in a wide range of lifestyle categories. Players Networks current original channels, Players Network, Vegas on Demand, Real Vegas TV, focus on Las Vegas and Gaming Lifestyles and the newest Channel is WeedTV. They are distributed over PNTVs owned and operated VOD Channels on TV in over 23,000,000 homes over Comcast, its Broadband Network and Mobile Platforms, on Hulu, Google, YouTube, Blinkx and Yahoo Video, on DVD, and through worldwide television syndication. For more information please visit www.playersnetwork.com

Statement under the Private Securities Litigation Reform Act:

With the exception of the historical information contained in this Release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to: the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.

CONTACT:

Media Inquiries:

Lisa Mayo-DeRiso

702.576.2659

Investor Relations

Parker Mitchell

702-575-9157

(DIDG) Signs First Agreement with Vivid Entertainment, LLC

HOLLYWOOD, CA / October 10, 2014 / Digital Development Group (DIDG) continues to add more content to its growing list of programming. With the addition of a new network, The Erotic Film Network (EFN), DIDG will expand its offerings into the world of adult entertainment. The Erotic Film Network, (EFN), has signed a long- term agreement with Vivid Entertainment, the “gold standard” of adult programming. Vivid’s library encompasses over three decades, focused on the videos of premiere adult stars, parodies, as well as multiple forms of adult lifestyle. The programming will be edited for mainstream Internet.

“This bold move towards the adult world is not a change, but an expansion,” said enthused company CEO, Martin W. Greenwald. “The Erotic Film Network, (EFN), is our platform to bring diverse adult content to the Internet. In addition to Vivid Entertainment, we are in the final stage of negotiations with several other noted adult entertainment providers. We are aggregating content from multiple studios, a strategy that allows us to become the hub within the industry. The rights we have acquired, not only affords us the ability to reach US viewers, but also stream content worldwide.”

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Digital Development Group Corp. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Digital Development Group Corp. undertakes no obligation to revise these statements following the date of this news release. Additional details of the Company’s business can be found in its public disclosures as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. Please refer to our full disclaimer, which includes our safe harbor statement, by clicking on or copying this link below into your browser: http://www.globenewswire.com/newsroom/ctr?d=10095182&l=9&u=http%3A%2F%2Fwww.movieandmusicnetwork.com%2Fsecfilings

Contact:

zack@movieandmusicnetwork.com

(GOHE) Announces Planned Buy-Back of Common Stock

Management Believes Stock is Undervalued and a Buyback is in the Best Interests of Shareholders

San Diego, Oct. 10, 2014  — Global Payout, Inc. (OTC Pink: GOHE), an emerging leader in payment solutions, announced today that from time to time the Company intends to purchase up to 1 million (1,000,000) shares of its common stock in this round in the open market.  The buyback is being initiated due to management’s belief that the stock is currently undervalued.

CEO Jim Hancock commented, “Never have the market opportunities for Global Payout been so great, and the Board of Directors strongly believes that the Company’s common stock is undervalued at this time.  As a result, we feel that now is the time to initiate a stock buyback program.”

This buyback program is a continuation of a stock repurchase program implemented by the Company in 2011.

Global Payout recently closed its acquisition of Maxie Mobile, Inc., a mobile financial services technology provider focused on underserved markets in the United States and globally.  The Maxie Mobile app is a universal financial solution on a mobile platform and has existing customers in the telecommunications and hotel and gaming industries.  The financial services delivered by the Maxie Mobile app includes bill payment, payroll deposits, check cashing, prepaid phone top up, and cross border remittances.  According to the World Bank, global remittances alone are expected to total $581 billion in 2014 and rise to $681 billion for 2016.

About Global Payout, Inc.

Global Payout, Inc. (www.globalpayout.com) is an emerging leader in the financial technology sector serving the needs of the world’s mobile population.  With the acquisition of Maxie Mobile, a comprehensive, cloud based payment solution platform built for mobile phones, tablets and computers, the Company is positioned to meet the needs of the estimated billions of unbanked, under-banked and unhappily banked consumers worldwide.  The Maxie Mobile app, which operates on all major mobile phone platforms and with all major carriers, gives users secure access to services including bill payment, payroll deposits, cross border remittances, check cashing, prepaid phone top up, and free long distance calling.  With an integrated prepaid card, users can purchase products online or at retail locations as well as access cash at ATMs worldwide.

Shareholders who would like to receive email notifications when new information, including press releases, investor newsletters, SEC filings or other information, is disclosed by the Company, are asked to send their names and email addresses to investors@globalpayout.com.  Those interested in following the progress of the Company can also engage with @GlobalPayout on Twitter.

Forward-Looking Statements Disclosure:

This press release may contain “forward-looking statements” within the meaning of the federal securities laws. In this context, forward looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” “will” and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward looking statements are based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

CONTACT: Global Payout, Inc.
         Investor Relations
         investors@GlobalPayout.com
         1-800-594-4350

(PMBSD) Hemp-Derived-Cannabinoid-Based Non-Prescription Epilepsy Medication Nearly Ready

SCHOFIELD, Wis., Oct. 10, 2014  — PuraMed BioScience^®, Inc., (OTCPink: PMBSD), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it is nearing the completion of development of its new non-prescription, hemp-based, homeopathic medication for treatment of epilepsy symptoms including seizures and seizure-related headaches.

Both epilepsy and migraines appear to be triggered by the same coritcal spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many people who suffer from migraines are prescribed epilepsy medications.

The third most common neurological disorder in the US, epilepsy affects approximately 2.7 million people, with children and older adults being most susceptible. The condition also causes up to 50,000 sudden deaths each year.

Recent research has shown cannabidiol (CBD), one of the hemp-derived cannabinoids, to be an effective therapy in the treatment of epilepsy symptoms.

“By incorporating standardized hemp oil into our current patented, over-the-counter migraine relief formula, MigraPure, we believe we can offer relief to people who not only suffer with migraines, but also offer relief to people who have seizure-related headaches and other epilepsy-type symptoms,” said Russ Mitchell, CEO, PuraMed BioScience. “Due to the close association between migraine headaches and epilepsy, the development of a hemp-based treatment for epilepsy symptoms is a logical step for the Company to make. Hemp-based cannabinoids combined with our experience in building herbal medicines that outperform traditional allopathic treatments fit extremely well with our unique delivery systems and our business philosophy.”

About MigraPure Advanced Migraine Relief

MigraPure (clinically tested as LipiGesic M) is an advanced homeopathic feverfew and ginger gel formulation which has been shown to be highly effective in the treatment of migraine and migraine associated symptoms. MigraPure has an excellent safety profile and has no reported drug interactions. During the double-blind, placebo-controlled clinical trial, participants who suffered acute migraine experienced relief (mild to no pain) in 64 percent of migraine occurrences.

MigraPure (f/k/a LipiGesic M) was also selected as one of 16 formulations and the only over-the-counter medication cited in an article co-authored by Dr. Roger Cady entitled, Advances in Drug Development for Acute Migraine. MigraPure was the only product described by Dr. Cady as “an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options.” The article was published in Drugs, a top-tier medical journal.

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products, which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts.

In addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience plans to launch additional hemp-based, cannabinoid-enhanced, anti-inflammatory and anxiolytic products as it moves forward in the development of its cannabinoid product line. www.PuramedBioScience.com

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com

(FPFI) Announces Successful Validation of High Pressure Processed New Juices

Soon-to-Be-Launched Harvest Soul Organic Chewable Juice Posts Positive Safety Results From Clinical Validation Studies — Seen as Fresher through Pressure(TM)

(SIMH) Sells Almost 100 Caregiver(R) TouchFree(TM) Clinical Thermometers To Fight #Ebola

MIAMI, Oct. 10, 2014 — Sanomedics International Holdings, Inc. (OTCQB:SIMH); “Sanomedics” or the “Company”); a medical technology holding company that focuses on providing game changing products, services and ideas, announced today that the Company’s Thermomedics, Inc. division has shipped the first group of devices to Atlanta Headquarters of the Center for Disease Control (“CDC”) for immediate distribution to selected ports of entry, where touch-free temperatures are destined to identify fevers in arriving travelers from at-risk countries.

Keith Houlihan, President of Sanomedics, noted that “Caregiver TouchFree™ Thermometers are uniquely suited to this type of highly infectious virus, since the method of transfer is via contact with body fluids and contaminated substances from the victims.”

He added that “Thermomedics is pleased to be able to supply this revolutionary instrument for use in the battle against the current threat to the nation’s health and security. Using no probe covers and patient contact means that there is less contaminated waste attributable to the temperature screening process.”

During a television interview Thursday on Miami’s local Fox affiliate WSVN, Houlihan mentioned that authorities have been quick to recognize the technology’s accuracy, safety, and strong clinical documentation.

Thermomedics’ VP of Marketing and Sales, Ron Benincasa, indicated that the speed of the process (1-2 seconds), simplicity of technique (point and press one button), and protection of the temperature-takers make this an ideal tool in this urgent effort.

The Company has dramatically increased production requirements to meet the escalating demand for the Caregiver, not only for the CDC needs, but in response to the growing adoption of these devices in healthcare facilities across the United States.

About Sanomedics International Holdings, Inc.

Sanomedics International Holdings, Inc. (OTCQB:SIMH) is a medical technology holding company that focuses on game changing products, services and ideas — a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. Sanomedics plans to grow existing business organically and through strategic acquisitions specifically relating to healthcare technology and services.

Make sure you are first to receive timely up-to-date information on Sanomedics and its subsidiaries. Sign up for Sanomedics email news alert system today at: http://ir.stockpr.com/sanomedics/email-alerts.

Also be sure to follow Sanomedics on Twitter https://twitter.com/sanomedics and tweet us (@Sanomedics) your questions and comments. We would love to hear from you!

Forward Looking Statements

This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition is not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company’s periodic filings with the Securities and Exchange Commission should be viewed for a complete understanding of risk and uncertainty.

CONTACT: Keith Houlihan
         info@Sanomedics.com
         305-433-7814

(HKUP) iHookup Social Receives Apple App Store Approval for Release

App Store Video Preview to Provide Expanded Visibility

(MLYCF) Closes Oversubscribed Private Placement, Grants Stock Options

VANCOUVER, Oct. 9, 2014  – American CuMo Mining Corporation (“CuMoCo” or the “Company”) (TSXV: MLY; OTCQX: MLYCF) is pleased to announce that its non-brokered private placement of up to 10,000,000 units (“CuMoCo Units”) at a price of Cdn$0.05 per unit for gross proceeds of up to $500,000 (the “CuMoCo Offering”), announced on August 20, 2014, has been closed and oversubscribed. The Board of Directors approved an increase to the size of the CuMoCo Offering, and the Company has sold a total of 11,000,000 CuMoCo Units for total gross proceeds of $550,000. A portion of the proceeds of the CuMoCo Offering will be applied to reduce the Company’s working capital deficit and the remainder for general corporate purposes.

Each CuMoCo Unit consists of one common share of the Company and one share purchase warrant (a “Warrant”) exercisable to purchase one common share of the Company at a price of Cdn $0.10 per common share until October 9 2016, subject to an acceleration provision whereby the term of the Warrants may be accelerated in the event that the Company’s common shares trade at or above a price of Cdn $0.12 per share for a period of 10 consecutive trading days. In such case, the Company may, at its option, accelerate the expiry date by delivery of notice to the holder and issuing a press release announcing such acceleration, and, in such case, the expiry date of the Warrants shall be deemed to be the 20th day following the later of the date on which the acceleration notice is sent to the holder of the Warrants and the date of issuance of the press release. All securities issued pursuant to the CuMoCo Offering will be subject to a four month hold period, expiring on February 10, 2015.

Insiders and their associated parties, each being a “related party” of the Company (as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”)), have subscribed for a total of 4,170,000 CuMoCo Units, as follows: Shaun Dykes (President, CEO and a director of the Company) and his associated parties, for 2,200,000 CuMoCo Units; John Moeller (a director of the Company) and an associated party, for 1,620,000 CuMoCo Units; Trevor Burns (Vice-President, Corporate Communications, Interim CFO and a director of the Company) for 100,000 CuMoCo Units; and Joseph Baird (a director of the Company) for 250,000 CuMoCo Units. The Company has relied upon the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 based on the fact that the fair market value of the related party participation in the CuMoCo Offering will not exceed 25% of the Company’s market capitalization prior to the closing of the CuMoCo Offering. The Board of Directors approved the participation of insiders in the CuMoCo Offering with the individual insiders who are directors abstaining from voting on their participation.

The Company also announces that it has granted options to purchase up to 300,000 common shares of the Company to each of Thomas Conway and Trevor Burns, the two most recently appointed directors, at a price of $0.35 per share exercisable for a period of five years.

In other financing news, the Company is in advanced negotiations regarding the silver streaming financing announced August 20, 2014 and in discussions with parties interested in providing the funds necessary to complete a Bankable Feasibility Study for the CuMo Project. Further news will be announced if and when agreements are entered into.

About CuMoCo

CuMoCo is focused on advancing its CuMo Project towards feasibility and establishing itself as one of the largest and lowest-cost molybdenum producers in the world as well as a significant producer of copper and silver. Management is continuing to build a strong foundation from which to move the Company and the CuMo Project forward. For more information, please visit www.cumoco.com and www.cumoproject.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this new release.

Forward-looking information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including, but not limited to, statements that address activities, events or developments that the Company expects or anticipates will or may occur in the future, such the Company’s ability to move its CuMo Project to feasibility and production, and to become one of the largest and lowest-cost molybdenum producers in the world as well as a significant producer of copper and silver. Forward-looking information is based on a number of material factors and assumptions, including the result of exploration activities, the ability of the Company to raise the financing for a feasibility study and to put the CuMo project into production, that no labour shortages or delays are experienced, that plant and equipment function as specified that the Court will not intervene with the Company’s proposed exploration activities at the CuMo Project, and the ability of the Company to obtain all requisite permits and licenses to advance the CuMo Project and eventually bring it into production. Forward-looking information involves known and unknown risks, future events, conditions, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future prediction, projection or forecast expressed or implied by the forward-looking information. Such factors include, among others, the interpretation and actual results of current exploration activities; changes in project parameters as plans continue to be refined; future prices of molybdenum, silver and copper; possible variations in grade or recovery rates; labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing, as well as those factors disclosed in the Company’s publicly filed documents, including the Company’s Management’s Discussion and Analysis for the period ended March 31, 2014.  There may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

(ZGSI) Establishes Two Operating Subsidiaries

Zero Gravity Solutions, Inc. (ZGSI or the “Company”) (Pink Sheets: ZGSI) announced today that it has established two wholly-owned subsidiaries, BAM Agricultural Solutions, Inc. and Zero Gravity Life Sciences, Inc. BAM Agricultural Solutions has commenced manufacturing, sales and revenue generation through the receipt of commercial-quantity orders for the Company’s first agricultural product, BAM-FX. Zero Gravity Life Sciences will continue ongoing research and development work in conjunction with NASA and other institutions.

The Company has added to its senior management team in order to effectively manage these companies. Mr. Glenn Stinebaugh, who has been involved in sustainable economic development and agricultural projects worldwide for over 25 years, has been named President and CEO of BAM Agricultural Solutions, Inc. Mr. Stinebaugh has been actively involved in the Company’s sales and marketing activities for several months. Mr. Stinebaugh stated, “I have been impressed with the BAM-FX product, its efficacy, place in the market and initial customer response. I plan to implement a robust marketing, distribution and customer support plan and augment the manufacturing infrastructure.”

Mr. Richard Godwin will shift from his position as President and CEO of ZGSI, while remaining a director, to become President and CEO of Zero Gravity Life Sciences, Inc. Mr. Harvey Kaye, currently serving as Chairman of the Board of ZGSI, will assume the titles of President and Interim CEO of ZGSI. Mr. Godwin stated, “This repositioning will allow me to fully focus on our NASA relationships, our research and development for BAM-FX and future products for the Company’s expanding agricultural IP.”

”The Company’s senior management team now has its key officers in the most effective roles to best accomplish the Company’s objectives of rapid revenue generation, the scale up of manufacturing to meet anticipated demand and continuing the ongoing end user customer and NASA sponsored research and development to build the companies’ pipeline of agricultural products,” stated Harvey Kaye, Chairman, President and Interim CEO of ZGSI.

About Zero Gravity Solutions, Inc.

Zero Gravity Solutions, Inc. is an agricultural biotechnology public company commercializing its technology derived from and designed for Space with significant applications on Earth. These technologies are focused on providing valuable solutions to challenges facing world agriculture. ZGSI’s two primary categories of technologies aimed at sustainable agriculture are: 1) BAM-FX™, an organic, cost effective, ionic nutrient delivery system for plants and 2) Directed Selection™, utilized in the development and production, in the prolonged zero/micro gravity environment of the International Space Station, large volumes of Non-GMO, novel, patentable stem cells with unique and beneficial characteristics. Additional information may be accessed at www.zerogsi.com.

Like us on Facebook

Follow us on Twitter

This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, acceptance of the Company’s products, increased levels of competition for the Company, new products and technological changes, the Company’s dependence on third-party suppliers, and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.

(KIWB) Operational Update For The Third Quarter 2014

NEW YORK, Oct. 9, 2014  — Kiwibox.com  [“Kiwibox” – KIWB.OB] is pleased to announce the activity and user development in the third quarter ended September 30, 2014.

THIRD QUARTER OPERATIONAL HIGHLIGHTS OF KIWIBOX GROUP

• Active Members  –  3.13 Million as of September 30, 2014, an increase of 12 % and 9 % from the 2^nd quarter 2014
• New Registrations  –  261,584 in 3rd quarter 2014, an increase of 11 % from the 2^nd quarter 2014.
• Unique Visitors  –  4.92 Million in 3rd quarter 2014, an increase of 12 % from the2^nd quarter 2014.
• Page Impressions  –  532 Million in 3rd quarter 2014, an increase of 4.1 % from the 2^nd quarter 2014.
• Guestbook Entries  –  37 Million as of September 30, 2014, an increase of 3.1 % from the 2^nd quarter 2014.
• Blog Entries  –  36.1 Million as of September 30, 2014, an increase of 2.2 % from the 2^nd quarter 2014.

“Even in the tough summer market, when everyone has decreasing numbers due to weather and outdoor activities, the Kiwibox Network enjoyed continued growth in all areas. During the high peaks of activity last quarter, the Kiwibox.com website itself had up to 6,000 new registrations per day,” said Andre Scholz, CEO and President of Kiwibox. “This was only possible by virtue of our concentrated data and knowledge exchange alliance with our affiliate, the KWICK! Community based in Germany and its subsidiary a global Internet Service Provider.”

Kiwibox.com expects to report its 3rd quarter 2014 financial results around October 30th, 2014.

Market  Position

The Kiwibox Network is in a unique position because it combines the excitement of a dating community with the benefits and accessibility of a real social network. The Kiwibox network encourages members to explore local events in their area, connect with other members and enjoy the additional member exclusive benefits the social network is offering, like games, blogging, chatting, picture-sharing and online-flirting.

Technology  Development

The Kiwibox network is focusing on the fast growing mobile usage phenomenon. The Kiwibox Network has released multiple Updates in the 3^rd quarter for its iOS and Android Applications. At present, more than 500,000 company Apps are installed in the marketplace. Kiwibox plans to release several more monthly updates for its existing Apps and another two new mobile Apps by the end of the year. The company plans to integrate online shopping features with benefits for its members in 4^th quarter 2014.

About Kiwibox.com: Company History

Kiwibox.com was initially founded in 1999 to give teenagers a voice on the Internet and was a leader in the teen oriented world for several years. In August 2007, the company was bought by Magnitude Information Systems, Inc., a publicly listed company. In the first quarter of 2011, Kiwibox.com acquired Pixunity.de a photo blogging community. On September 30, 2011 Kiwibox.com acquired the German social network community KWICK!, finalizing the acquisition in May 2012 and currently our 20% owned German affiliate. Kiwibox common shares are listed on the over-the-counter, Bulletin Board market under the symbol KIWB.OB.

This press release contains certain statements relating to future results, which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from either historical or anticipated results, depending on a variety of factors, which include but are not limited to, statements regarding the company’s potential acquisitions, its ability to obtain financing for these acquisitions, its ability to integrate any acquisition into its business and operations and manage such processes, its ability to expand its membership, users and internet brand and its projected financial results. The company’s actual results could differ materially from those predicted or implied and reported results should not be considered as an indication of future performance. Factors that could cause or contribute to such differences include, but are not limited to: the after effects of the global economic downturn, changes in political, business and economic conditions, including any conditions that affect ecommerce growth; fluctuations in foreign currency exchange rates; the company’s ability to deal with the increasingly competitive ecommerce environment, including competition for its targeted internet audiences, potential advertisers and, in general, from other social networks; the company’s need and ability to manage other regulatory, tax and litigation risks as its services become offered in more jurisdictions and applicable laws become more restrictive; any changes the company may make to its market approach and offerings; the company’s ability to upgrade and develop its systems, infrastructure and user-member service capabilities at reasonable cost; and the company’s ability to maintain site stability and performance on its site while adding new products and features in a timely fashion. The forward-looking statements in this release do not include the potential impact of any acquisitions or divestitures that may be announced and/or completed after the date hereof.

(ESPI) Establishes Credit Facility With Transfac Capital

New Credit Line Provides Up to $4M in Financing With Reduced Cost of Capital Over Previous Line

LAFAYETTE, La., Oct. 9, 2014  — ESP Resources, Inc. (OTCQB:ESPI), an oil and gas services company, announced that its wholly-owned subsidiary, ESP Petrochemicals, Inc. (collectively, the “Company”), has entered into a factoring agreement for up to $4,000,000 (the “Agreement”) with Transfac Capital, Inc. (“Transfac”). The Agreement replaces the Company’s previous factoring facility that carried a higher interest rate.

David Dugas, President & CEO stated, “When we decided in early 2013 to discontinue certain non-core divisions and focus on our core production petrochemical business, our expectation was that we would gain new customers. We are pleased to announce that we have been successful in those efforts with the acquisition of 11 new customers in the regions of South Louisiana, North and South Texas and Southern Oklahoma. With the acquisition of these new customers, our revenue has increased substantially in this third quarter of 2014 compared to the third quarter last year. We anticipate the same positive trends in the coming quarters and the continued improvement of our cash flows and gross margins.” Mr. Dugas continued, “This new credit line with Transfac bolsters our working capital needs so that we can support our supply chain and service our pipeline of business with new and existing customers.”

More information regarding the Agreement is incorporated by reference to the Company’s Current Report on Form 8-K, as filed with the SEC on October 8, 2014.

About ESP Resources, Inc.

ESP Resources, Inc. is a publicly traded oil and gas services company headquartered in Lafayette, Louisiana. The Company manufactures, blends, distributes and markets specialty chemicals and analytical services to the oil and gas industry. The Company’s senior management has over 100 years of combined operating experience in the oil and gas services industry. More information is available on the Company’s Website at www.espchem.com.

Legal Notice Regarding Forward-Looking Statements

This press release contains “forward looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Forward looking statements are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Information concerning oil or natural gas reserve estimates may also be deemed to be forward looking statements, as it constitutes a prediction of what might be found to be present when and if a project is actually developed. Actual results may differ materially from those currently anticipated due to a number of factors beyond the reasonable control of the Company. It is important to note that actual outcomes and actual results could differ materially from those in such forward-looking statements.

Readers are cautioned not to place undue reliance on the forward-looking statements made in this press release. In evaluating these statements, you should consider the risks discussed, from time to time, in the reports we file with the U.S. Securities & Exchange Commission. For a discussion of some of the risks and important factors that could affect the Company’s future results and financial condition, see the Company’s Form 10-Ks and 10-Qs on file with the U.S. Securities & Exchange Commission.

CONTACT: David Dugas
         President and Chief Executive Officer
         ESP Resources, Inc.
         david.dugas@espchem.com
         (337) 706-7056

(WTCG) Subsidiary, AdMedia Group, Inc., Starts Indiegogo Crowdfunding Campaign